tbuckley/cabot-search huggingface dataset:
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Authors: Matthew Ingham, Jacob B. Allred, Katherine Gano, Suzanne George, Steven Attia, Melissa Amber Burgess, Mahesh Seetharam, Sosipatros Alexandros Boikos, Nam Bui, James Lin Chen, Julia Lee Close, Gregory Michael Cote, Premal H. Thaker, S. Percy Ivy, Biswajit Das, Geoffrey Shapiro, Bose Kochupurakkal, Jane B. Trepel, Yves Pommier, Gary K. Schwartz
Journal: Journal of Clinical Oncology (2021)

11506 Background: Uterine leiomyosarcoma (uLMS) is an aggressive sarcoma subtype with frequent metastatic relapse. After failure of front-line chemotherapy, remaining options provide limited benefit (trabectedin: ORR 11%, mPFS 4.0 mos; pazopanib: ORR 11%, median PFS 2.9 mos; dacarbazine: ORR 9%, mPFS 1.5 mos). Recent molecular studies suggest uLMS harbors characteristic defects in the homologous recombination (HR) DNA repair pathway, including somatic biallelic BRCA2 deletion in 10%, implicating potential sensitivity to PARP-inhibitor based treatment approaches. In preclinical uLMS models in which temozolomide (T, an oral equivalent to dacarbazine) or the PARP inhibitor olaparib (O) showed limited single agent activity, the combination of T + O was highly effective in inhibiting uLMS tumor growth and promoting apoptosis. Methods: NCI protocol #10250 is a single-arm, open-label, multi-center phase II study evaluating T + O in advanced uLMS. Pts had progression on ≥ 1 prior line and ECOG PS ≤ 2. Pts received T 75 mg/m 2 PO daily + O 200 mg PO BID days 1-7 in 21-day cycles. Primary endpoint was ORR. A one-stage binomial design was used. If ≥ 5/22 responded, the treatment was considered promising (95% power; α = 0.06). All pts underwent paired tumor biopsies. Correlative assays to evaluate for HR deficiency (whole exome sequencing/RNAseq, RAD51 foci formation) and for intrinsic PARP inhibitor resistance (SLFN11 expression) will be correlated with response. Results: 22 patients were evaluable (median age 55, median prior treatment lines 3). Median follow-up was 10.8 mos. Primary endpoint, ORR within 6 mos of initiating treatment, was 23% (5/22). Overall ORR was 27% (6/22). Median PFS was 6.9 mos (95% CI: 5.4 mos – not estimable (NE)). Median duration of response (DOR) was 12.0 mos (95% CI: 9.5 mos – NE). Hematologic toxicity was common (grade 3/4 neutropenia, 77%; thrombocytopenia 32%) but manageable with dose modification. Correlative assays are ongoing with plans to present at the meeting. An immunohistochemical assay for RAD51 foci has been adapted for uLMS samples and clearly distinguishes BRCA2- deleted and wild-type tumors. Conclusions: NCI 10250 met the prespecified primary efficacy endpoint of ORR in a population of patients with heavily pre-treated uLMS. Responses are durable (median DOR 12 mos). Correlative assays are being completed to evaluate whether uLMS tumors with HR deficiency or with preserved SLFN11 expression are most sensitive to T + O and may underlie durable responses. A randomized study of the combination is planned. Clinical trial information: NCT03880019.
Left ventricular volume-time curves generated by real-time 3D echocardiography: A new quantitative approach for detecting diastolic dysfunction Ziad Zeidan, Thomas Buck, Joerg Barkhausen, Thomas Bartel, Joerg Debatin, Raimund Erbel. Department of Cardiology, University of Essen, Essen, Geramny, Dept. of Radiology, University of Essen, Essen, Germany
Journal: Journal of the American College of Cardiology (2001)
Clinical outcome of germ cell cancer patients (pts) treated with high-dose chemotherapy with stem cell support (HDC) –a single center experience
Authors: E. G. Dos Santos, F. Leal-Da-costa, N. Miranda, A. Machado, A. Guimaraes, I. Ferreira, M. Abecasis, J. L. Passos-Coelho
Journal: Journal of Clinical Oncology (2004)

4724 Background: Pts with International Germ Cell Cancer Collaborative Group (IGCCCG) "poor prognosis" disease achieve only a 41% 5-year progression-free survival (PFS) with standard chemotherapy. Pts who do not achieve a complete remission with BEP chemotherapy or who relapse after such treatment have a still worse prognosis. The clinical impact of HDC in such pts is still unclear. Methods: Pts with germ cell cancer with IGCCCCG "poor prognosis" disease at diagnosis (or, earlier, with Indiana group C) or with recurrent or refractory (i.e., less than marker negative partial remission) disease after initial BEP chemotherapy were eligible for HDC. Results: Between June 1996 and April 2003, 18 pts underwent one (13 pts) or two (5 pts) cycles of HDC with ICE (ifosfamide 10g/m2, carboplatin 1,500mg/m2 and etoposide 2,400mg/m2); 17 pts), or etoposide (1500mg/m2) plus thiotepa (900 mg/m2); 1 pt), in 6 pts as consolidation after BEP and in 12 pts for recurrent disease (7 pts) or refractoriness to BEP (5 pts). In the consolidation group (6 pts), with a median follow-up of 42 months (range 10–72 months), there are no events. Thus the PFS and overall survival (OS) at 3.5 years is 100%. In contrast, with a median follow-up of 18 months, the median PFS and OS for pts with recurrent or refractory disease subgroup are 4 months (0–40+) and 18 months (4–40+), respectively. In this subgroup, 10 pts relapsed by 8 months post-HDC and only 2 are progression-free at 20 and 40 months. Conclusions: Despite the small number of pts and short follow-up, these results compare at least as favorably to the outcome obtained with standard chemotherapy in pts with "poor prognosis" at diagnosis. In contrast the outcome of pts with recurrent or refractory disease after initial BEP chemotherapy are not better than those obtained with standard salvage chemotherapy. No significant financial relationships to disclose.
Abstract P013: Association Between Serum Chemerin Levels and Coronary Heart Disease: A Meta Analysis
Authors: Pradyumna Agasthi, Sivakanth Aloor, Avantika Chenna, Vivek Menon, Rachel Harris
Journal: Circulation (2016)

Background: Chemerin is a novel adipokine linked with obesity, metabolic syndrome and chronic inflammatory diseases. It plays a pivotal role in modulating adipocyte differentiation, activation of macrophages and production of proinflammatory cytokines. It is hypothesized that chemerin promotes vascular remodeling and endothelial dysfunction leading to the development of coronary atherosclerosis. We conducted a meta-analysis to evaluate the relationship between serum chemerin levels and coronary heart disease (CHD). Methods: We searched MEDLINE, CINAHL and COCHRANE databases for studies reporting serum chemerin levels in the patients with CHD and healthy controls. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum chemerin levels between the CHD and control groups.We performed residual maximum likelihood meta-regression analysis on covariates age, BMI and female sex. Results: Our search strategy yielded 43 articles and we included 10 studies enrolling 2225 participants. The median age and body mass index(BMI) of the CHD group was 62 yrs (IQR 60-63) and 26 kg/m 2 (IQR 26-28) vs 61 yrs (IQR 58-62) and 26 kg/m 2 (IQR 24-27) in the control group. The median percentage of female population was lower in the CHD group at 39% (IQR 22-52) vs 49% (IQR 31-53) in the control group. The unweighted median serum chemerin levels in the CHD group were 33.3 ng/ml (IQR 25.4-63.2) compared to 29.8 ng/ml (IQR 15.2-38.2) in the control group. The SMD of serum chemerin level was 0.78 (95% CI 0.39 - 1.17) P &lt;0.001 comparing those in the CHD group and control group. This association was not explained by age, BMI or sex. Conclusion: An elevated serum chemerin level is significantly associated with presence of CHD. Chemerin can potentially used as a novel biomarker and to risk stratify patients with CHD.
Hepatic Steatosis and Portal Hypertension with Presinusoidal Obstruction
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: Nature Immunology (2000)

In the November 2000 issue of Nature Immunology Figure 1a and b were printed incorrectly, although the online version and PDF are correct.Below are the correct figure parts, along with the relevant part of the legend.Figure 1.Suppression of NK92 lytic function by PI3K inhibitors.Blockade of (a) perforin and (b) granzyme B movement by inhibition of PI3K or MEK.NK92 cells pretreated with DMSO, PD98059 (PD, 50 µM), LY294002 (LY, 50 µM) or wortmannin (WM, 50 nM) were mixed with equal numbers of Raji tumor cells for 5 min at 37 o C. The cytospun cells were then stained with (a) FITC-anti-perforin and TRITC-anti-IgM (b) or with FITC-anti-granzyme B and TRITC-anti-IgM.
From the Centers for Disease Control and Prevention. False-positive serologic tests for human T-cell lymphotropic virus type I among blood donors following influenza vaccination, 1992
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unresting Cells
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Winter Desire
Authors: Zijad Duraković
Journal: Annals of Internal Medicine (2000)

Ad Libitum17 October 2000Winter DesireZijad Duraković, MDZijad Duraković, MDZagreb, Croatia (Duraković)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-8-200010170-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A voice across a rusty wireTrembling in an iron treeIn the head of noisy fireA desire to be free.Out of that icy winterFrom a day wet and grayThrough clouds to a space outerTo forget this foggy day. Author, Article, and Disclosure InformationAffiliations: Zagreb, Croatia (Duraković)Corresponding Author: Zijad Duraković, MD, Antuna Bauera Str. 19, 10000 Zagreb, Croatia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 October 2000Volume 133, Issue 8Page: 655 ePublished: 17 October 2000 Issue Published: 17 October 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Operating Room Procedure. For Nurses and Internes.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Work-Related Injuries and Illnesses Associated With Child Labor—United States, 1993
Journal: JAMA (1996)

During 1993, an estimated 2.1 million persons aged 16-17 years in the United States were employed. Although many children aged <16 years work, employment data are neither routinely collected nor reported for this age group, and there are no reliable estimates of the number of children in this age group who work. During summer months, when most children are not in school, employment and hours worked by children aged <18 years increase substantially. To characterize workplace-related health and safety hazards for children, CDC's National Institute for Occupational Safety and Health (NIOSH) analyzed 1993 data for workers aged <18 years from the Survey of Occupational Injuries and Illnesses (SOII), a survey administered by the Bureau of Labor Statistics (BLS), U.S. Department of Labor. This report summarizes the results of this analysis and indicates that substantial numbers of persons aged <18 years sustain work-related injuries and illnesses each year.
DIVISION OF ENVIRONMENTAL MEDICINE AND MEDICAL SERVICES
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QUACK ADVERTISEMENTS IN RELIGIOUS PAPERS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
960 CHOLESTEROL REGULATES MITOCHONDRIAL RAFT-LIKE DOMAINS DURING TNF/FAS-MEDIATED HEPATOCELLULAR APOPTOSIS
Authors: N. Matias, A. Fernandez, V. Manganelli, A. Colell, A. Tinari, W. Malorni, C. Garcia-Ruiz, M. Sorice, J.C. Fernandez-Checa
Journal: Journal of Hepatology (2010)
Redefining Death
Authors: James M. Humber
Journal: JAMA (1987)

One of the pleasures in reviewing books is that every so often the reviewer gets to read a text that is intellectually stimulating, meticulously organized, and well argued.<i>Redefining Death</i>is such a book. Gervais begins by distinguishing between<i>concepts</i>of death and<i>criteria</i>for declaring death. She then argues persuasively that different criteria presuppose different concepts of human death, and that a proper analysis of the concept of human death is necessary if we are to justify the use of any criterion for declaring death. After Gervais has clarified the relationship between concepts of death and criteria for declaring that death has occurred, she argues that although the brain-death criterion is widely accepted, it has not been given adequate conceptual support. With this in mind, she examines three competing analyses of the concept of human death. These are (1) biologic analyses, which conceive of human beings as organisms and
TIME TO PLAN FOR CONTINUING STUDY
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reovirus Infections in Children and Young Adults
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Lecture on a Remarkable Case of Abscess of the Dura Mater and Brain, following a Blow on the Head
Authors: I. B. Yeo
Journal: BMJ (1879)

GEN-rLEMEN,-I wish to direct your attention to-day to the particulars of a case of great practical as well as pathological interest, which has been in this hospital under my care during the past winter.Allow me to say, however, that the interest of the case does not by any means rest solely on the mere fact that it is a rare one, though that it certainly is.You may remember the remark made by Mr. Lister at the aut- opsy: " that it might not fall to the lot of any of you to see more than one such case in a lifetime".I say it is not merely because the case is a rare one that it becomes an interesting one; it is interesting because it brings into striking relief facts of general pathological significance and importance.